长春瑞滨联合顺铂治疗蒽环及紫衫类耐药晚期乳腺癌患者临床观察及不良反应分析.docVIP

长春瑞滨联合顺铂治疗蒽环及紫衫类耐药晚期乳腺癌患者临床观察及不良反应分析 　　 【摘 要】 目的 观察长春瑞滨联合顺铂治疗蒽环及紫衫类耐药的晚期乳腺癌患者的临床疗效和不良反应。方法 选择2011年10月至2014年5月在我院接受治疗的对蒽环及紫衫类耐药的晚期乳腺癌患者70例。联合应用长春瑞滨及顺铂进行化疗，长春瑞滨25mg/m2 ，第1、8天进行静脉滴注;顺铂25mg/m2 ，第1～3天进行静脉滴注，三周为一个疗程，2个疗程后评价患者的临床疗效和不良反应。结果 70例患者中有5例完全缓解，29例部分缓解，26例疾病稳定，10例疾病进展，有效率为48.57%。不良反应有胃肠道反应、骨髓抑制和肝肾功能损伤等，以上不良反应多为Ⅰ～Ⅱ级毒性反应，Ⅲ～Ⅳ级毒性反应较少。结论 长春瑞滨联合顺铂治疗蒽环及紫衫类耐药的晚期乳腺癌患者疗效较好，不良反应在可控制范围内，值得在临床推广使用。 　　 【关键词】 长春瑞滨 顺铂 蒽环及紫衫类 晚期乳腺癌 不良反应 　　Clinical observation and analysis of adverse reactions of vinorelbine combined with cisplatin in the treatment of patients with anthracycline- and taxane-refractory advanced breast cancer 　　Li Guiqin 　　Department of Clinical Pharmacy，Pharmaceutical Department，Nanhua Affiliated Hospital of University of South China，Hengyang 421002 　　 【Abstract】 Objective To observe the clinical observation and analysis of adverse reactions of vinorelbine combined with cisplatin in the treatment of patients with anthracycline and taxane-refractory advanced breast cancer. Method 70 cases of patients with advanced breast were selected staying in our hospital for treatment of anthracene ring and purple shirts resistant in October 2011 to May 2014.Combining use of vinorelbine and cisplatin chemotherapy， 25 mg/m2 of vinorelbine， 1， 8 days used intravenous drip; 25 mg/m2 of cisplatin ， 1 ～ 3 days used intravenous drip， three weeks as a cycle， evaluated the patients clinical curative effect and adverse reactions after two cycle. Results 5 cases had complete remission （CR） in 70 cases of patients ， 29 cases had partial response （PR） ， 26 cases had stable disease （SD）， 10 cases had disease （PD） ， the effective rate was 48.57%. Adverse reactions included bone marrow suppression of gastrointestinal reaction and function of liver and kidney damage， most of the above adverse reactions wereⅠ ～ Ⅱ toxicity reaction， grade Ⅲ ～ Ⅳ toxicity reaction was relatively rare. Conclusions The effect of patients with advanced breast cancer of changchun rui marina combined cispla